Vaccines, Biosimilars In Shadow As Sun Shines On Ranbaxy?
This article was originally published in PharmAsia News
Executive Summary
Sun Pharma may eliminate biosimilars and vaccines work that was being done by Ranbaxy at its two units in Hyderabad and Bangalore. The move could symbolize the thinking of Sun management – to stay away from venturing into product segments that are highly competitive or still evolving.